However, the absence of existing inhibitors of both ALKBH3 and NHEJ1 undermines their importance as a therapeutic strategy to prevent or minimize the chance of ALL disease relapse after complete remission. The gene discussed is NHEJ1; the disease is acute lymphoblastic leukemia.